Qilu Evening News Qilu One Point reporter Zhang Wenke
April 6, 2022 – 8 On the 3rd, the Shanghai Composite Index fluctuated slightly, with a cumulative decline of 0.94% on the 3rd. The Shenzhen Component Index showed a downward trend, with a cumulative decline of 2.20% on the 3rd; the ChiNext Index and the Kechuang 50 both fell by more than 3%.
Affected by this, only 8 of the 29 A-share listed companies in Zibo achieved a cumulative increase in their stock prices this week, and the remaining 21 fell in varying degrees.
Among them, Jinjing Technology became the biggest gainer in Zibo A shares this week with a cumulative increase of 7.36% on the 3rd, while Longquan shares and Triumph New Materials rose by 5.44% and 4.54% respectively, ranking second and third on the list of gainers bit.
This week, for Zibo pharmaceutical listed companies, there are 3 companies that ushered in good news.
Among them, Jincheng Pharmaceutical issued an announcement on April 6 that its holding subsidiary Jincheng Jinsu received a notice from the State Food and Drug Administration on ceftezole sodium for injection, cefmetazole sodium for injection, Supplementary approval for cefodizime sodium for injection. The approval document shows that this application meets the relevant requirements for drug registration, and it is agreed to change the marketing authorization holder of the above-mentioned drugs from Hainan Guangshengyu to Jincheng Jinsu in accordance with relevant regulations.
In this regard, Jincheng Pharmaceutical stated that after obtaining the above-mentioned drug registration approval, the company’s cephalosporin product pipeline has been enriched, which is conducive to further enhancing the market competitiveness of the company’s cephalosporin series products.
Not only that, but also on April 6, Jincheng Pharmaceutical stated in another announcement that its wholly-owned subsidiary Jincheng Suzhi Cefadroxil Capsules passed the consistency evaluation of the quality and efficacy of generic drugs.
According to reports, the product has passed the quality and efficacy consistency evaluation of generic drugs, which is conducive to further improving the technical level of the product, improving market competitiveness, and accumulating valuable materials for the follow-up products to carry out generic drug consistency evaluation work. experience.
On the evening of April 7, Xinhua Pharma issued a non-public offering of A-shares listing announcement. The announcement showed that 37,091,988 new shares will be added to the non-public offering and will be listed on the Shenzhen Stock Exchange on April 13. , the issuer is Hualu Investment, and the subscription amount is about 250 million yuan.
Qilu Evening News Qilu Yidian found that after this issuance, Hualu Investment will become the third largest shareholder of Xinhua Pharma, with a shareholding ratio of 6.16%.
It is understood that the funds raised after the non-public offering of Xinhua Pharmaceuticals after deducting the issuance expenses are all used to repay interest-bearing liabilities and supplement working capital, of which the repayment of interest-bearing debts does not exceed 140 million yuan, and the remaining part Supplement company liquidity.
Xinhua Medical announced on the evening of April 7 that the company has recently received the “Medical Device Registration Certificate of the People’s Republic of China” issued by the State Drug Administration and Shandong Provincial Drug Administration. Blood irradiation equipment is registered as a Class III medical device; medical air compressors are registered as a Class II medical device.
The announcement stated that the approval for listing of dual-source X-ray blood irradiation equipment and medical air compressors can provide customers with a variety of choices, enrich Xinhua Medical’s radiation diagnosis and treatment product line and medical gas product system, and improve The product sequence of X-ray blood irradiation equipment is conducive to enhancing the company’s core competitiveness.
In terms of individual stocks, Qixiang Tengda surpassed Inke Medical with a total market value of 24.73 billion yuan and became the “market value king” of Zi stocks this week, and Inke Medical followed closely with a total market value of 24.52 billion yuan. After Dongyue Silicon Materials ranked third, with a total market value of 18.58 billion yuan.